CRISPR Therapeutics (CRSP) recently showcased new preclinical results for its CTX460 therapy, revealing strong gene and mRNA correction in animal models for Alpha-1 Antitrypsin Deficiency. The ...

Lilly’s upfront offer for Adverum, the developer of a gene therapy for age-related macular degeneration, is less than the ...

Genenta Science shares surged by more than double Friday after the company said it has partnered with Anemocyte to collaborate on its plasmid DNA technology platform. The stock was briefly halted from ...

Eli Lilly said on Friday it would acquire gene therapy developer Adverum Biotechnologies in a deal valued at up to $261.7 ...

Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...

Beam Therapeutics recently announced that its BEAM-302 program received FDA orphan drug designation, alongside encouraging updates for its gene-editing therapies targeting rare diseases such as sickle ...

Biotech company Metagenomi (NASDAQ:MGX) is utilizing artificial intelligence chips from Amazon Web Services (AMZN) to enhance ...

Gene editing, led by CRISPR, is expanding rapidly beyond medical applications, offering new opportunities across various biotech industries. Technological breakthroughs are fueling acceleration and ...

As global demand for wheat continues to rise, climate change, limited farmland, and population growth make it increasingly ...

As developers of gene editing therapies and other genetic medicines get set to report third quarter earnings in coming days, analysts and especially investors will keep their eyes on whether the ...